We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders

By LabMedica International staff writers
Posted on 07 Sep 2026

Neurodevelopmental disorders comprise a heterogeneous group of conditions that often emerge early in life and can be difficult to diagnose. More...

Families may face prolonged searches for answers when the underlying genetic cause has not yet been linked to a defined syndrome. Establishing clear gene-disease relationships can reduce uncertainty and guide clinical evaluation. New findings now identify a previously unrecognized genetic form of neurodevelopmental disorder.

University of Otago (Dunedin, New Zealand) researchers identified ELAVL2 variants as the cause of a previously undefined neurodevelopmental disorder and delineated its clinical features. The work, published in The American Journal of Human Genetics, classifies an ELAVL2-related neurodevelopmental disorder characterized by prominent cognitive, behavioral, and neurological features. The study involved an international collaboration between teams at Otago and in the Netherlands.

Investigators used international gene databases to assemble individuals worldwide who harbored ELAVL2 alterations and shared clinical presentations, including developmental delay and intellectual disability. Functional analyses showed that some variants change the gene’s biological activity, consistent with ELAVL2 haploinsufficiency underlying the disorder. By linking genotype with phenotype, the team established ELAVL2 as a disease gene and formalized the entity as an ELAVL2-related neurodevelopmental disorder.

According to the study authors, the work has already provided answers for 15 individuals and families who participated in the research. The discovery offers a structured basis for case recognition and variant interpretation in clinical genetics. The researchers indicate that ongoing investigations are examining additional members of the ELAVL gene family for similar roles in neurodevelopment and disease.

“Neurodevelopment depends on precise orchestration of the dosage, location and timing of gene expression. Before the study, the gene ELAVL2 was known to have an important role in helping influence brain development, but no one had connected it with a genetic condition. We have now discovered variants in this gene are the cause of a previously undefined neurodevelopmental disorder. The work has helped provide answers for 15 individuals and families who were part of the research and has the potential to help many more,” said Dr. Meghan Mulligan, of the Department of Biochemistry.

“Our discovery not only helps those whānau involved in the study—who now have an answer as to the cause of their family member's neurological condition—but also opens up a new diagnostic pathway for other families with rare and previously unexplained neurodevelopmental disorders. Diagnostic labs globally will be able to use our findings to help other families searching for an answer and potentially receive a genetic diagnosis in a much shorter time frame,” added Mulligan.

Related Links
University of Otago


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.